Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-16
2007-01-16
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S062000
Reexamination Certificate
active
10684212
ABSTRACT:
The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by progesterone receptor. Also provided are methods of making such compounds and pharmaceutical compositions.
REFERENCES:
patent: 3635941 (1972-01-01), Weaver et al.
patent: 3907507 (1995-09-01), Rivera
patent: 5506102 (1996-04-01), McDonnell et al.
patent: 5693646 (1997-12-01), Jones et al.
patent: 5693647 (1997-12-01), Jones et al.
patent: 5696127 (1997-12-01), Jones et al.
patent: 5994544 (1999-11-01), Jones et al.
patent: 6093826 (2000-07-01), Edwards et al.
patent: 6268497 (2001-07-01), Edwards et al.
patent: 6380207 (2002-04-01), Coghlan et al.
patent: 6448405 (2002-09-01), Jones et al.
patent: 6506766 (2003-01-01), Coghlan et al.
patent: 6696459 (2004-02-01), Jones et al.
patent: 2004/0147530 (2004-07-01), Zhi et al.
patent: 2004/0152718 (2004-08-01), Zhi et al.
patent: 2015351 (1970-10-01), None
patent: 0513387 (2000-03-01), None
patent: 04 316557 (1992-11-01), None
patent: 96/19458 (1996-06-01), None
patent: 9619458 (1996-06-01), None
patent: 97/49709 (1997-12-01), None
patent: WO 99/41256 (1999-08-01), None
patent: 200202565 (2001-06-01), None
patent: WO 99/41257 (2002-04-01), None
patent: 2004033459 (2004-04-01), None
patent: 2004033460 (2004-04-01), None
patent: 2004033461 (2004-04-01), None
Berger, T. S., et al., Interaction of Glucocorticoid Analogues with the Human Glucocorticoid Receptor. J. Steroid Biochem. Mol. Bio. 1992, 41, 733-738.
Pathirana, C., et al., Nonsteroidal Human Progesterone Receptor Modulators from the Marine Alga Cymopolia Babata. Mol. Pharm. 1995, 47, 630-635.
Zhi, Lin et al., “Development of Progesterone Receptor Antagonists From 1,2-Dihydrochromeno [3,4-f] Quinoline Agonist Pharmacophore”,Bioorganic&Medicinal Chemistry Letters, 13 (2003), 2075-2078.
International Search Report for related PCT International Application No. PCT/US03/24420, filed Aug. 4, 2003 (dated Feb. 18, 2004).
Clemm et al., “Definition of the critical cellular components which distinguish between hormone and antihormone activated progesterone receptor,” Journal of Steroid Biochemisry and Molecular Biology 53(1-6):487-495, (1995).
Edwards et al., “5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents,” Journal of Medicinal Chemistry. 41(3):303-310 (1998).
Edwards et al., “Preparation, resolution, and biological evaluation of 5-aryl-1, 2-dihydro-5H-chromeno[3,4-f] quinolines: potent, orally active, nonsteroidal progesterone receptor agonists,” Journal of Medicinal Chemistry 41(15):2779-2785 (1998).
Hamann et al., “Nonsteroidal progesterone receptor antagonists based on a conformationally-restricted subseries of 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines,” Bioorganic & Medicinal Chemistry Letters 8(19):2731-2736 (1998).
McDonnell et al., “Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors,” Seminars in Cancer Biology, 5(5):327-336 (1994).
Miner, J. N. and C.M. Tyree, “Drug discovery and the intracellular receptor family,” Vitamins and Hormones. 62:253-280. (2001).
Rosen et al., “Intracellular receptors and signal transducers and activators of transcription superfamilies - novel targets for small-molecule drug discovery,” Journal of Medicinal Chemistry 38(25):4855-4874 (1995).
Santiso-Mere, D. and D.P. McDonnell, “Applied nuclear receptor research in the drug discovery process,” Chimica Oggi. 12(5-6):29-36. (1994).
Silverman, R.B., “Prodrugs and Drug Delivery Systems,” Chapter 8 in The Organic Chemistry of Drug Design and Drug Action, San Diego: Academic Press, Inc., pp. 352-401 (1992).
Tegley et al., “5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists,” Journal of Medicinal Chemistry. 41(22):4354-4359. (1998).
Vegeto et al., “Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function,” Molecular Endocrinology. 7(10):1244-1255. (1993).
Wagner et al., “The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: Implications for the development of dissociated antiprogestins,” Endocrinology 140(3):1449-1458 (1999).
Wen et al., “The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells,” Molecular and Cellular Biology 14(12):8356-8364 (1994).
Zhi, L. and K.B. Marschke, “Novel class of non-steroidal progesterone receptor antagonists,” Expert Opinion on Therapeutic Patents. 9(6):695-700 (1999).
Zhi et al., “5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators,” Bioorganic & Medicinal Chemistry Letters 8(23):3365-3370 (1998).
Zhi, et al. “Synthesis and biological Activity of 5-Methylidine 1,2-Dihydrochromeno[3,4-f]quinoline Derivatives as Progesterone Receptor Modulators” Bioorganic & Medicinal Chemistry Letters 13:2071-2074 (2003).
Zhi et al., “5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists,” Journal of Medicinal Chemistry 41(3):291-302 (1998).
Zhi et al., “5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effort of A-ring modification,” Journal of Medicinal Chemistry. 42(8):1466-1472 (1999).
Zhi et al., “5-Benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as Selective Progesterone Receptor Modulators,” Journal of Medicinal Chemistry 46(19):4104-4112 (2003).
Berger et al. “Interaction of Glucocorticoid Analogues with the Human Glucocorticoid Receptor,” J. Steroid Biochem. Molec. Biol., vol.41, No. 3-8, pp. 733-738 (1992).
Brown, J.P. and L.M. Jackman, “Reactions of 2,2-Dialkyl-1,2-dihydroquinolines. Part II. Bromo-derivatives of 1,2-Dihydro-2,2,4-trimethylquinoline,” Journal of the Chemical Society, Sep. 1964, pp. 3132-3140.
Chemical Abstracts, vol. 87, No. 13, Sep. 26, 1977 (Sep. 26, 1977), Abstract No. 102120c for: Migachev,et al., “Synthesis of substituted derivatives of 6H-dibenzo [b,d]pyran-6-one,” Khim. Geterotsikl. Soedin. (1977), (5), 703-4.
Cook et al., “Reversal of Activity Profile in Analogs of the Antiprogestin RU 486: Effect of a 16a-Substituent on Progestational (Agonist) Activity,” Life Sciences vol. 52, pp. 155-162 (1992).
Database CAPLUS, Chemical Abstracts AN=1975:111718 for Endel'man et al. “[N-phenylanthranilic acids with fluorine-containing substituents],” Ukr. Khim. Zh. (Russ. Ed.) vol. 40, No. 12, pp. 1295-5 (1974).
Database CAPLUS, Chemical Abstracts AN=118:147477 for Japanese Patent Publication No. JP 04316557, published Nov. 6, 1992, Kono et al., entitled: “Preparationof 6-aryl-cyclic anthranilic acids and their use as therapeutics for treatment of metabolic bone disorder”.
Database CAPLUS, Chemical Abstracts AN=70:87515 for Kost et al., “Pyridylation of 1-alkyl-1,2,3,4-tetrahydroquinolines,” Khim. Geterotsikl. Soedin., Sb., 1: Azotsoderzhashchie Geterotsikly (1967), pp. 248-53, Editor(s): Hillers, S., Publisher: Izd. “Zinatne” Riga, USSR.
Database CAPLUS, Chemical Abstracts AN=1993:613822 for Samsonova et al., “Spectroscopic studies of photoreactions in aminocoumarins,” Kvantovaya Elektron (Kiev) vol. 41, pp. 63-72 (1992).
Database CAPLUS, Chemical Abstracts AN=1992:22860 for Song, et al., “Solvent effect of nonradiative transition yield for coumarin derivative,” Chinese Science Bulletin, vol. 36, No. 12, pp. 1000-1003, (1992).
Datebase Crossfire Beilstein 'Online!, XP 002002687, BRN=8809
Karanewsky Donald S.
Pedram Bijan
Van Oeveren Cornelis Arjan
Zhi Lin
Aulakh Charanjit S.
Fish & Richardson P.C.
Ligand Pharmaceuticals Incorporated
Miskiel Frank J.
Seidman Stephanie
LandOfFree
5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3805619